Skip to main content

Advertisement

SpringerLink
Log in

NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers

  • Original Article—Alimentary Tract
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

An Erratum to this article was published on 16 May 2015

Abstract

Background

Although serum NY-ESO-1 antibodies (s-NY-ESO-1-Abs) have been reported in patients with esophageal carcinoma, this assay system has not been used to study a large series of patients with various other cancers.

Patients and methods

Serum samples of 1969 cancer patients [esophageal cancer (n = 172), lung cancer (n = 269), hepatocellular carcinoma (n = 91), prostate cancer (n = 358), gastric cancer (n = 313), colorectal cancer (n = 262), breast cancer (n = 365)] and 74 healthy individuals were analyzed using an originally developed enzyme-linked immunosorbent assay system for s-NY-ESO-1-Abs. The optical density cut-off value, determined as the mean plus three standard deviations for serum samples from the healthy controls, was fixed at 0.165. Conventional tumor markers were also evaluated in patients with esophageal carcinoma.

Results

The positive rate of s-NY-ESO-1-Abs in patients with esophageal cancer (31 %) was significantly higher than that in the other groups: patients with lung cancer (13 %), patients with hepatocellular carcinoma (11 %), patients with prostate cancer (10 %), patients with gastric cancer (10 %), patients with colorectal cancer (8 %), patients with breast cancer (7 %), and healthy controls (0 %). The positive rate of s-NY-ESO-1-Abs was comparable to that of serum p53 antibodies (33 %), squamous cell carcinoma antigen (36 %), carcinoembryonic antigen (26 %), and CYFRA 21-1 (18 %) and gradually increased with the tumor stage.

Conclusions

The positive rate of s-NY-ESO-1-Abs was significantly higher in patients with esophageal cancer than in patients with the other types of cancers. On the basis of its high specificity and sensitivity, even in patients with stage I tumors, s-NY-ESO-1-Abs may be one of the first choices for esophageal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

CEA:

Carcinoembryonic antigen

PBS:

Phosphate-buffered saline

SCC:

Squamous cell carcinoma

SCC-Ag:

Squamous cell carcinoma antigen

s-NY-ESO-1-Abs:

Serum NY-ESO-1 antibodies

References

  1. Shimada H, Yajima Satoshi, Oshima Yoko, et al. Impact of serum biomarkers on esophageal squamous cell carcinoma. Esophagus. 2012;9:131–40.

    Article  Google Scholar 

  2. Shimada H, Nabeya Y, Okazumi S, et al. Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery. 2003;133:486–94.

    Article  PubMed  Google Scholar 

  3. Shimada H, Nabeya Y, Okazumi S, et al. Prognostic significance of CYFRA 21-1 in patients with esophageal squamous cell carcinoma. J Am Coll Surg. 2003;196:573–8.

    Article  PubMed  Google Scholar 

  4. Lubin R, Zalcman G, Bouchet L, et al. Serum p53 antibodies as early markers of lung cancer. Nat Med. 1995;1:701–2.

    Article  PubMed  CAS  Google Scholar 

  5. Shimada H, Kagaya A, Shiratori T, et al. Detection of anti-CUEC-23 antibodies in serum of patients with esophageal squamous cell carcinoma: a possible new serum marker for esophageal cancer. J Gastroenterol. 2009;44:691–6.

    Article  PubMed  CAS  Google Scholar 

  6. Shimada H, Takeda A, Arima M, et al. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer. 2000;89:1677–83.

    Article  PubMed  CAS  Google Scholar 

  7. Shimada H, Nabeya Y, Okazumi S, et al. Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery. 2002;132:41–7.

    Article  PubMed  Google Scholar 

  8. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A. 1997;94:1914–8.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  9. Xu YW, Peng YH, Chen B, et al. Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma. Am J Gastroenterol. 2014;109:36–45.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  10. Mashino K, Sadanaga N, Tanaka F, et al. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer. 2001;85:713–20.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  11. Shan Q, Lou X, Xiao T, et al. A cancer/testis antigen microarray to screen autoantibody biomarkers of non-small cell lung cancer. Cancer Lett. 2013;328:160–7.

    Article  PubMed  CAS  Google Scholar 

  12. Healey GF, Lam S, Boyle P, et al. Signal stratification of autoantibody levels in serum samples and its application to the early detection of lung cancer. J Thorac Dis. 2013;5:618–25.

    PubMed  PubMed Central  Google Scholar 

  13. Yang Z, Chevolot Y, Géhin T, et al. Improvement of protein immobilization for the elaboration of tumor-associated antigen microarrays: application to the sensitive and specific detection of tumor markers from breast cancer sera. Biosens Bioelectron. 2013;40:385–92.

    Article  PubMed  CAS  Google Scholar 

  14. Nakamura S, Nouso K, Noguchi Y, et al. Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma. J Gastroenterol Hepatol. 2006;21:1281–5.

    Article  PubMed  CAS  Google Scholar 

  15. Middleton CH, Irving W, Robertson JF, et al. Serum autoantibody measurement for the detection of hepatocellular carcinoma. PLoS ONE. 2014;9:e103867.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Fujiwara S, Wada H, Kawada J, et al. NY-ESO-1 antibody as a novel tumour marker of gastric cancer. Br J Cancer. 2013;108:1119–25.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  17. Gati A, Lajmi N, Derouiche A, et al. NY-ESO-1 expression and immunogenicity in prostate cancer patients. Tunis Med. 2011;89:779–83.

    PubMed  Google Scholar 

  18. Long YY, Wang Y, Huang QR, et al. Measurement of serum antibodies against NY-ESO-1 by ELISA: a guide for the treatment of specific immunotherapy for patients with advanced colorectal cancer. Exp Ther Med. 2014;8:1279–84.

    PubMed  PubMed Central  Google Scholar 

  19. Kagohashi K, Satoh H, Ishikawa H, et al. A re-evaluation of squamous cell carcinoma antigen (SCC) as a serum marker for non-small cell lung cancer. Med Oncol. 2008;25:187–9.

    Article  PubMed  CAS  Google Scholar 

  20. Shimada H, Ochiai T, Nomura F. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer. 2003;97:682–9.

    Article  PubMed  Google Scholar 

  21. Wada H, Isobe M, Kakimi K, et al. Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. J Immunother. 2014;37:84–92.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank the Ministry of Education, Culture, Sports, Science and Technology of Japan for Grants-in-Aid for Scientific Research (nos. 24591961 and 21591717).

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Surgery, School of Medicine, Toho University, Tokyo, Japan

    Yoko Oshima, Hideaki Shimada, Satoshi Yajima, Tatsuki Nanami, Seiko Ohtsuka & Hironori Kaneko

  2. Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, Japan

    Kazuyuki Matsushita & Fumio Nomura

  3. Division of Gastroenterological Surgery, Chiba Cancer Center, Chiba, Japan

    Osamu Kainuma, Nobuhiro Takiguchi, Hiroaki Soda, Hiroshi Yamamoto & Matsuo Nagata

  4. Division of Urology, Chiba Cancer Center, Chiba, Japan

    Takeshi Ueda

  5. Division of Thoracic Disease, Chiba Cancer Center, Chiba, Japan

    Toshihiko Iizasa

  6. Division of Breast Surgery, Chiba Cancer Center, Chiba, Japan

    Naoto Yamamoto

  7. Division of Clinical Genomics, Chiba Cancer Center, Chiba, Japan

    Sana Yokoi

  8. Division of Pathology and Cell Therapy, Chiba Cancer Center, Chiba, Japan

    Masatoshi Tagawa

  9. Medical & Biological Laboratories Co., Ltd, Nagoya, Japan

    Akiko Kuwajima & Akihiro Murakami

Authors
  1. Yoko Oshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hideaki Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Satoshi Yajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tatsuki Nanami
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kazuyuki Matsushita
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fumio Nomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Osamu Kainuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nobuhiro Takiguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hiroaki Soda
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takeshi Ueda
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Toshihiko Iizasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Naoto Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hiroshi Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Matsuo Nagata
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Sana Yokoi
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Masatoshi Tagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Seiko Ohtsuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Akiko Kuwajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Akihiro Murakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Hironori Kaneko
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideaki Shimada.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oshima, Y., Shimada, H., Yajima, S. et al. NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers. J Gastroenterol 51, 30–34 (2016). https://doi.org/10.1007/s00535-015-1078-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-015-1078-8

Keywords

Search

Navigation